Pleiotrophic functions of Epstein-Barr virus nuclear antigen-1 (EBNA-1) and oriP differentially contribute to the efficiency of transfection/expression of exogenous gene in mammalian cells

Journal of Biotechnology

Volumn 133, Issue 2, 2008, Pages 201-207

  Kishida, Tsunao ^a   Asada, Hidetsugu ^a   Kubo, Koji ^b   Sato, Yuko T ^b   Shin Ya, Masaharu ^a   Imanishi, Jiro ^a   Yoshikawa, Kenichi ^b   Mazda, Osam ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Artificial chromosome; EBNA1; Transfection

Indexed keywords

ARTIFICIAL CHROMOSOME; CYTOPLASM-TO-NUCLEAR TRANSPORT; MAMMALIAN CELLS; PLEIOTROPHIC FUNCTIONS; TRANSFECTION;

ANTIGENS; CELLS; DNA; GENE EXPRESSION;

VIRUSES;

EPSTEIN BARR VIRUS ANTIGEN; ORIP PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; CYTOPLASM; ELECTROPORATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; CHROMOSOMES, ARTIFICIAL; CYTOPLASM; DNA REPLICATION; DNA, VIRAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION; GENOME, VIRAL; HELA CELLS; HUMANS; K562 CELLS; MICE; PLASMIDS; REPETITIVE SEQUENCES, NUCLEIC ACID; REPLICATION ORIGIN; TRANSCRIPTION, GENETIC; TRANSFECTION;

HUMAN HERPESVIRUS 4; MAMMALIA;

EID: 37249084096     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2007.08.035     Document Type: Article

References (31)

1. Ambinder R.F., Mullen M.A., Chang Y.N., Hayward G.S., and Hayward S.D. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J. Virol. 65 (1991) 1466-1478
2. Asada H., Kishida T., Hirai H., Satoh E., Ohashi S., Takeuchi M., Kubo T., Kita M., Iwakura Y., Imanishi J., and Mazda O. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin-12 (IL-12) and IL-18 by means of the EBV/lipoplex. Mol. Ther. 5 (2002) 609-616
3. Chaudhuri B., Xu H., Todorov I., Dutta A., and Yates J.L. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10085-10089
4. Cui F.D., Kishida T., Ohashi S., Asada H., Yasutomi K., Satoh E., Kubo T., Fushiki S., Imanishi J., and Mazda O. Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein-Barr virus (EBV)-based plasmid vectors. Gene Ther. 8 (2001) 1508-1513
5. Dhar S.K., Yoshida K., Machida Y., Khaira P., Chaudhuri B., Wohlschlegel J.A., Leffak M., Yates J., and Dutta A. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 106 (2001) 287-296
6. Fischer N., Kremmer E., Lautscham G., Mueller-Lantzsch N., and Grasser F.A. Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin alpha2. J. Biol. Chem. 272 (1997) 3999-4005
7. Gahn T.A., and Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J. Virol. 69 (1995) 2633-2636
8. Hebert E. Improvement of exogenous DNA nuclear importation by nuclear localization signal-bearing vectors: a promising way for non-viral gene therapy?. Biol. Cell 95 (2003) 59-68
9. Hirai K., and Shirakata M. Replication licensing of the EBV oriP minichromosome. Curr. Top. Microbiol. Immunol. 258 (2001) 13-33
10. Jankelevich S., Kolman J.L., Bodnar J.W., and Miller G. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. EMBO J. 11 (1992) 1165-1176
11. Kishida T., Asada H., Satoh E., Tanaka S., Shinya M., Hirai H., Iwai M., Tahara H., Imanishi J., and Mazda O. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 8 (2001) 1234-1240
12. Krysan P.J., and Calos M.P. Epstein-Barr virus-based vectors that replicate in rodent cells. Gene 136 (1993) 137-143
13. Krysan P.J., Haase S.B., and Calos M.P. Isolation of human sequences that replicate autonomously in human cells. Mol. Cell Biol. 9 (1989) 1026-1033
14. Lechardeur D., and Lukacs G.L. Intracellular barriers to non-viral gene transfer. Curr. Gene Ther. 2 (2002) 183-194
15. Lupton S., and Levine A.J. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol. Cell Biol. 5 (1985) 2533-2542
16. Mazda O. Application of Epstein-Barr virus (EBV) and its genetic elements to gene therapy. In: Cid-Arregui A., and Garcia-Carranca A. (Eds). Viral Vectors: Basic Science and Gene Therapy (2000), Eaton Publishing, Natick, MA 325-337
17. Mazda O. Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors. Curr. Gene Ther. 2 (2002) 379-392
18. Mazda O., and Kishida T. Functional nucleotide sequences capable of promoting nonviral genetic transfer. In: Taira K., Kataoka K., and Niidome T. (Eds). Non-Viral Gene Therapy: Gene Design and Delivery (2005), Springer-Verlag, Tokyo 198-210
19. Mazda O., Satoh E., Yasutomi K., and Imanishi J. Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. J. Immunol. Methods 204 (1997) 143-151
20. Mazda O., Teshigawara K., Fujimoto S., Hattori N., Dou Y.M., and Katsura Y. A reporter system using a flow cytometer to detect promoter/enhancer activity in lymphoid cell lines. J. Immunol. Methods 169 (1994) 53-61
21. Middleton T., and Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J. Virol. 68 (1994) 4067-4071
22. Nakanishi H., Mazda O., Satoh E., Asada H., Morioka H., Kishida T., Nakao M., Mizutani Y., Kawauchi A., Kita M., Imanishi J., and Miki T. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Ther. 10 (2003) 434-442
23. Puglielli M.T., Woisetschlaeger M., and Speck S.H. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J. Virol. 70 (1996) 5758-5768
24. Rawlins D.R., Milman G., Hayward S.D., and Hayward G.S. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 42 (1985) 859-868
25. Reisman D., and Sugden B. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell Biol. 6 (1986) 3838-3846
26. Reisman D., Yates J., and Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Cell Biol. 5 (1985) 1822-1832
27. Sugden B., and Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J. Virol. 63 (1989) 2644-2649
28. Tomiyasu K., Satoh E., Oda Y., Nishizaki K., Kondo M., Imanishi J., and Mazda O. Gene transfer in vitro and in vivo with Epstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cells. Biochem. Biophys. Res. Commun. 253 (1998) 733-738
29. Tsurumi T., Fujita M., and Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev. Med. Virol. 15 (2005) 3-15
30. Wysokenski D.A., and Yates J.L. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J. Virol. 63 (1989) 2657-2666
31. Yates J.L., Warren N., and Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 (1985) 812-815